FDA Acceptance for Filing of New Drug Application (NDA) for Trientine Tetrahydrochloride (TETA 4HCl) for the treatment of Wilson ’s Disease
NDA supported by positive data from Phase 3 CHELATE clinical trial
TETA 4-HCl previously granted Orphan Drug Designation for first-line treatment of Wilson’s Disease
Paris, France– 02 September 2021 – Orphalan SA, a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news